Growth plate senescence, chondrocyte biology, and the growth hormone-insulin-like growth factor 1 axis in childhood growth. (PubMed, J Pediatr Endocrinol Metab) - Oct 4, 2026 - "Pathogenic variants in these local regulators underlie conditions such as achondroplasia and a minority of cases classified as idiopathic short stature, and mechanism-targeted therapies - including vosoritide, a C-type natriuretic peptide analog, together with the FGFR3-directed tyrosine kinase inhibitor infigratinib and the once-weekly CNP prodrug navepegritide - illustrate, for achondroplasia specifically, how targeting a defined paracrine lesion can produce growth responses that systemic hormone stimulation alone does not achieve in that disorder. For a limited group of monogenic growth-plate disorders, resolving these molecular networks is beginning to complement uniform systemic intervention with precision, mechanism-based therapy, although this paradigm remains investigational for the great majority of children with short stature."
Journal • Review • Genetic Disorders • Idiopathic Short Stature • FGFR3 • IGF1
|
|
Ashraf T Soliman; Fawzia Alyafei; Nada Alaaraj; Noor Hamed; Shayma Ahmed
|